10. SEGMENTS

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

10. SEGMENTS

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s ADMA BioManufacturing segment reflects the Company’s immune globulin manufacturing and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1). The Plasma Collection Centers segment consists of one and three FDA-licensed source plasma collection facilities located in Georgia for the six months ended June 30, 2019 and 2018, respectively. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended June 30, 2019
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	4,002,445		$	2,522,788		$	35,709		$	6,560,942
Cost of product revenue		8,170,381			2,320,855			—			10,491,236
Loss from operations		(8,671,783	)		(392,181	)		(2,274,710	)		(11,338,674	)
Interest and other expense, net		(246,603	)		(59	)		(1,626,536	)		(1,873,198	)
Net loss		(8,918,386	)		(392,240	)		(3,901,246	)		(13,211,872	)
Depreciation and amortization		688,848			113,958			3,287			806,093
Total assets		67,236,416			3,835,999			72,201,705			143,274,120

Three Months Ended June 30, 2018
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	2,144,724		$	2,476,117		$	35,709		$	4,656,550
Cost of product revenue		7,965,681			1,679,981			—			9,645,662
Loss from operations		(9,918,243	)		(941,993	)		(2,557,145	)		(13,417,381	)
Interest and other expense, net		(237,161	)		(436	)		(1,092,853	)		(1,330,450	)
Net loss		(10,155,404	)		(942,429	)		(3,649,998	)		(14,747,831	)
Depreciation and amortization		639,300			200,598			6,001			845,899
Total assets		54,297,915			5,438,645			58,015,432			117,751,992

Six Months Ended June 30, 2019
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	5,346,428		$	4,671,686		$	71,417		$	10,089,531
Cost of product revenue		16,110,727			3,785,688			—			19,896,415
Loss from operations		(19,292,591	)		(362,601	)		(4,891,898	)		(24,547,090	)
Interest and other (expense) income, net		(416,216	)		13,560			(2,895,007	)		(3,297,663	)
Gain on transfer of plasma center assets		—			11,527,421			—			11,527,421
Loss on extinguishment of debt		—			—			(9,962,495	)		(9,962,495	)
Net (loss) income		(19,708,807	)		11,178,380			(17,749,400	)		(26,279,827	)
Depreciation and amortization		1,376,240			228,199			6,983			1,611,422
Capital expenditures		224,440			21,235			—			245,675

Six Months Ended June 30, 2018
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	3,810,967		$	4,816,172		$	71,417		$	8,698,556
Cost of product revenue		18,663,323			3,225,087			—			21,888,410
Loss from operations		(22,642,709	)		(1,980,817	)		(5,326,358	)		(29,949,884	)
Interest and other expense, net		(477,214	)		(871	)		(2,142,004	)		(2,620,089	)
Net loss		(23,119,923	)		(1,981,688	)		(7,468,362	)		(32,569,973	)
Depreciation and amortization		1,271,131			389,512			14,796			1,675,439
Capital expenditures		591,665			454,710			—			1,046,375